Participate in promoting the Group’s scientific excellence around the world and offering access to quality healthcare for all.
countries in which the Group’s medicines are distributed
billion euros in sales in 2020/2021, including €3.3billion for brand-name medicines and €1.4 billion for generic medicines
médicaments génériques commercialisés dans plus de 60 pays
billion in sales in 2020/2021 generated by the Group’s four generic medicine subsidiaries: Biogaran, Egis, Pharlab and Swipha